Wedbush downgraded shares of Alto Neuroscience (NYSE:ANRO – Free Report) from an outperform rating to a neutral rating in a research report sent to investors on Wednesday, MarketBeat Ratings reports. Wedbush currently has $4.00 target price on the stock, down from their previous target price of $29.00.
ANRO has been the topic of several other reports. Robert W. Baird decreased their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Finally, Rodman & Renshaw downgraded Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.40.
Get Our Latest Research Report on Alto Neuroscience
Alto Neuroscience Price Performance
Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.07. Equities research analysts forecast that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Alto Neuroscience
Hedge funds and other institutional investors have recently made changes to their positions in the business. RA Capital Management L.P. acquired a new stake in Alto Neuroscience in the first quarter valued at approximately $21,267,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Alto Neuroscience in the first quarter valued at $9,788,000. Vanguard Group Inc. purchased a new position in shares of Alto Neuroscience in the first quarter valued at $8,233,000. Jennison Associates LLC acquired a new stake in Alto Neuroscience during the 1st quarter valued at $7,039,000. Finally, Artal Group S.A. purchased a new stake in Alto Neuroscience during the 1st quarter worth $5,372,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Recommended Stories
- Five stocks we like better than Alto Neuroscience
- What Does Downgrade Mean in Investing?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Ride Out The Recession With These Dividend Kings
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What Are Some of the Best Large-Cap Stocks to Buy?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.